# US 10,370,717 B2 · Methods for the measurement of post-traumatic stress disorder microRNA markers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,370,717 B2
- Document ID: US10370717B2
- Status: Granted
- Kind: B2
- Application number: 15/306,178
- Filed: 2015-04-21
- Published: 2017-02-16
- Granted: 2019-08-06
- Earliest claimed: 2014-04-22
- Assignees: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
- Applicants: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
- Inventors: Radha K. Maheshwari; Nagaraja S. Balakathiresan; Manish Bhomia; Raghavendar Chandran
- Web page: https://patentgrep.com/patent/US10370717B2

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention provides for methods of measuring levels of micro RNAs for the diagnosis, treatment and/or monitoring the progression of post-traumatic stress disorder (PTSD) or traumatic brain injury (TBI) in a subject having or suspected of having PTSD and/or TBI. The methods, in general comprise measuring levels of at least one of miR-142-5p, miR-19b, miR-1928, miR-223-3p, miR-322*, miR-324, miR-421-3p, miR-463* and miR-674* is a sample from a subject suffering from or suspected of having PTSD and/or TBI.

## Claims

### Claim 1

A process for administering a therapeutic agent for treating post-traumatic stress disorder (PTSD), the process comprising:
measuring levels of miR-19b-3p, miR-223-3p and miR-221-3p micro RNA in a biological sample obtained at a first time point from a subject suspected of suffering from PTSD, comprising hybridizing agents that specifically hybridize to each of the micro RNA, amplifying each of the micro RNA and sequencing the micro RNA to confirm the identity of each of the micro RNA and quantifying the identified RNA, and
administering a therapeutic for the treatment of PTSD based on the measurements of the micro RNA.

### Claim 2 (depends on 1)

The process of claim 1 wherein said biological sample is obtained at least thirteen days after said subject has been exposed to traumatic event likely to cause PTSD.

### Claim 3 (depends on 1)

The process of claim 1 wherein said biological sample is obtained within one week after said subject presents with clinical symptoms of PTSD.

### Claim 4 (depends on 1)

The process of claim 1, wherein said biological sample is obtained within 24 hours after said subject presents with clinical symptoms of PTSD.

### Claim 5 (depends on 1)

The process of claim 1 wherein said therapeutic agent is an antidepressant, an antipsychotic, or combinations thereof.

### Claim 6 (depends on 5)

The process of claim 5, wherein said therapeutic is fluoxitine and paroxatine, venlafaxine, sertraline, mirtazapine, olanzapine and quetiapione, propranolol, or an α1-selective adrenoceptor antagonist, or combinations thereof.

### Claim 7 (depends on 1)

The process of claim 1 wherein said biological sample is whole blood, plasma, serum, CSF, urine, saliva, sweat, prefrontal cortex tissue, hippocampus tissue, or ipsilateral cortex tissue.